tocilizumab-anoh 180 MG/ML per 0.9 ML Prefilled Syringe
- RxCUI
- 2705425
- RxNorm name
- tocilizumab-anoh 180 MG/ML per 0.9 ML Prefilled Syringe
- Display name
- tocilizumab-anoh 180 MG/ML per 0.9 ML Prefilled Syringe
- Full name
- tocilizumab-anoh 180 MG/ML per 0.9 ML Prefilled Syringe
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:00
Purple Book Biologic Products#
UNII Substances#
No records found.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 581c288f-8015-40ef-a4c3-683c96db193d | tocilizumab-anoh 162 MG in 0.9 ML Prefilled Syringe [PSN] · 0.9 ML tocilizumab-anoh 180 MG/ML Prefilled Syringe [SCD] · tocilizumab-anoh 162 MG per 0.9 ML Prefilled Syringe [SY] · tocilizumab-anoh 180 MG/ML per 0.9 ML Prefilled Syringe [SY] | 4 | 4 | These highlights do not include all the information needed to use AVTOZMA safely and effectively. See full prescribing information for AVTOZMA. AVTOZMA ® (tocilizumab-anoh) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2025 AVTOZMA (tocilizumab-anoh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful | 20260123 |
| 60381a7e-d7ae-4384-925d-c19c418d1663 | tocilizumab-anoh 162 MG in 0.9 ML Prefilled Syringe [PSN] · 0.9 ML tocilizumab-anoh 180 MG/ML Prefilled Syringe [SCD] · tocilizumab-anoh 162 MG per 0.9 ML Prefilled Syringe [SY] · tocilizumab-anoh 180 MG/ML per 0.9 ML Prefilled Syringe [SY] | 4 | 4 | These highlights do not include all the information needed to use TOCILIZUMAB-ANOH safely and effectively. See full prescribing information for TOCILIZUMAB-ANOH. TOCILIZUMAB-ANOH injection, for intravenous or subcutaneous use Initial U.S. Approval: 2025 Tocilizumab-anoh is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful dif | 20260123 |